New Insights into Aging: Targeting Immune Function to Improve Healthspan

Understanding Aging through Immune System Dynamics

Aging varies significantly among individuals but ultimately impacts everyone. Recent research from Stanford Medicine, conducted on mice and human cells, uncovers a specific immune system failure that could elucidate the aging process.

The Role of Tissue-Resident Macrophages

The study highlights the role of tissue-resident macrophages—immune cells residing within organs—that diminish in their ability to remove senescent neutrophils as individuals age. This decline in macrophage function is instrumental in the overall aging process.

When researchers blocked a specific receptor on these macrophages, they observed that multiple organs in mice exhibited more youthful characteristics, affecting the brain, heart, skeletal muscle, liver, spleen, bone marrow, kidney, and colon. This receptor responds to a hormone involved in inflammation and pain, impacting both mice and humans.

Linking Immune Response and Aging

Significantly, disabling this receptor in macrophages prevented various age-related health issues, such as frailty and cognitive decline. “We’ve been trying to figure out why we age,” remarked Dr. Katrin Andreasson, senior author of the research. “Now we know at least one big reason for it.”

The findings, detailed in a paper published in Science, provide fresh insights into how chronic inflammation contributes to aging and associated health complications, suggesting a potential drug strategy to mitigate these effects.

Senescence and its Consequences

Neutrophils, the most prevalent white blood cells, act as first responders to infections, yet they have a short lifecycle, typically lasting about 12 to 24 hours. As individuals age, the numbers of neutrophils increase, many of which enter a state of senescence without having encountered pathogens.

“Senescent neutrophils are killing our tissues,” Andreasson explained. “Clearance of these cells is essential for preventing chronic inflammation.” Macrophages, responsible for clearing such cellular debris, become less effective over time, which may explain some aspects of aging.

Prostaglandins and Macrophage Function

One pathway involved in this dysfunction pertains to prostaglandins, specifically one type called PGE2. This hormone rises in response to infections, injuries, and even normal aging, promoting inflammation by acting on receptors found in macrophages.

The study suggests that aging leads to higher levels of PGE2 and an increase in the number of EP2 receptors on macrophages, resulting in a feedback loop that undermines their ability to engulf senescent neutrophils.

As a result, these neutrophils accumulate, further contributing to inflammation. Previous work by Andreasson’s lab indicated that the metabolic functionality of macrophages wanes with age, which is critical as declining performance exacerbates the deterioration of tissue health.

Experimental Approaches: Genetic Insights and Findings

To probe deeper into the receptor’s implications, researchers created genetically modified mice capable of deleting the EP2 gene specifically in macrophages. Removing this receptor reinstated their ability to clear neutrophils, reversing some age-related disruptions.

In their comparison, younger mice (6-8 months old, akin to young adults) were compared with older mice (23-25 months, similar to seniors). They also analyzed older mice with the EP2 gene deleted during their younger phase. An analysis of 71 blood proteins revealed that 59 maintained youthful levels in older mice lacking EP2, particularly proteins from the liver, a major player in metabolic regulation.

Connection to Human Aging

Normal older mice displayed accumulations of senescent neutrophils in multiple organs, while those lacking EP2 showed markedly lower neutrophil levels, indicative of better macrophage function and healthier overall organ status. These mice exhibited traits of youth, including less visceral fat and improved physical fitness, leading to better performance in coordination and memory tasks.

This aging research is particularly timely, as it underscores the need for therapies targeting inflammatory responses without broadly inhibiting essential processes. Currently, there’s a lack of approved drugs that can selectively block EP2 without affecting other beneficial prostaglandins.

Future Directions in Therapeutics

To assess therapeutic potential, the research team administered an experimental EP2 inhibitor to older mice for two months. The treatment achieved a marked reduction in both total and senescent neutrophil levels, restoring some macrophage functions typically diminished with age.

A broader analysis of livers from different aged and diseased humans revealed similarly concerning trends with elevated neutrophil accumulation and compromised macrophage action linked to increased EP2 activity.

According to Andreasson, this marks a crucial step in understanding the mechanisms of aging at a cellular level and developing targeted therapeutic options. She emphasizes, “We need to develop a safe drug” aimed at blocking EP2 specifically, which could have significant implications for improving healthspan and mitigating age-related decline.